Emerging treatment options for myelofibrosis: Focus on pacritinib

Vivian Chow, Ashley Weissman, Casey Lee O’Connell, Azim Mehrvar, Mojtaba Akhtari

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dysregulation has led to many clinical investigations for new treatment approaches. This review provides practical knowledge on the disease state, an overview of treatment options, and specifically focuses on the efficacy and safety of pacritinib in the management of MF. Pacritinib is a novel selective inhibitor of JAK2 and FMS-related tyrosine kinase 3 (FLT3) currently in Phase III trials for the treatment of MF. Thus far, studies have demonstrated clinical efficacy in reducing splenomegaly and constitutional symptoms. Common adverse events were gastrointestinal in nature, while hematologic toxicity was limited. However, it was announced that all ongoing clinical trials on pacritinib have been placed on hold by the US Food and Drug Administration in February 2016, due to concerns for increased intracranial hemorrhage and cardiac events. With comprehensive risk-benefit analysis of clinical trial data, the utility of pacritinib in the management of MF may be more clearly defined.

Original languageEnglish (US)
Pages (from-to)2655-2665
Number of pages11
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - May 4 2016

Fingerprint

Primary Myelofibrosis
Clinical Trials
Janus Kinases
Intracranial Hemorrhages
Splenomegaly
United States Food and Drug Administration
Transducers
Protein-Tyrosine Kinases
Quality of Life
Safety
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
Neoplasms

Keywords

  • FLT3
  • JAK2
  • Myeloproliferative neoplasms
  • SB1518

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Chow, V., Weissman, A., O’Connell, C. L., Mehrvar, A., & Akhtari, M. (2016). Emerging treatment options for myelofibrosis: Focus on pacritinib. OncoTargets and Therapy, 9, 2655-2665. https://doi.org/10.2147/OTT.S93875

Emerging treatment options for myelofibrosis : Focus on pacritinib. / Chow, Vivian; Weissman, Ashley; O’Connell, Casey Lee; Mehrvar, Azim; Akhtari, Mojtaba.

In: OncoTargets and Therapy, Vol. 9, 04.05.2016, p. 2655-2665.

Research output: Contribution to journalReview article

Chow, V, Weissman, A, O’Connell, CL, Mehrvar, A & Akhtari, M 2016, 'Emerging treatment options for myelofibrosis: Focus on pacritinib', OncoTargets and Therapy, vol. 9, pp. 2655-2665. https://doi.org/10.2147/OTT.S93875
Chow V, Weissman A, O’Connell CL, Mehrvar A, Akhtari M. Emerging treatment options for myelofibrosis: Focus on pacritinib. OncoTargets and Therapy. 2016 May 4;9:2655-2665. https://doi.org/10.2147/OTT.S93875
Chow, Vivian ; Weissman, Ashley ; O’Connell, Casey Lee ; Mehrvar, Azim ; Akhtari, Mojtaba. / Emerging treatment options for myelofibrosis : Focus on pacritinib. In: OncoTargets and Therapy. 2016 ; Vol. 9. pp. 2655-2665.
@article{3505f7409d8d4fe2a47b38a250c79cbd,
title = "Emerging treatment options for myelofibrosis: Focus on pacritinib",
abstract = "Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dysregulation has led to many clinical investigations for new treatment approaches. This review provides practical knowledge on the disease state, an overview of treatment options, and specifically focuses on the efficacy and safety of pacritinib in the management of MF. Pacritinib is a novel selective inhibitor of JAK2 and FMS-related tyrosine kinase 3 (FLT3) currently in Phase III trials for the treatment of MF. Thus far, studies have demonstrated clinical efficacy in reducing splenomegaly and constitutional symptoms. Common adverse events were gastrointestinal in nature, while hematologic toxicity was limited. However, it was announced that all ongoing clinical trials on pacritinib have been placed on hold by the US Food and Drug Administration in February 2016, due to concerns for increased intracranial hemorrhage and cardiac events. With comprehensive risk-benefit analysis of clinical trial data, the utility of pacritinib in the management of MF may be more clearly defined.",
keywords = "FLT3, JAK2, Myeloproliferative neoplasms, SB1518",
author = "Vivian Chow and Ashley Weissman and O’Connell, {Casey Lee} and Azim Mehrvar and Mojtaba Akhtari",
year = "2016",
month = "5",
day = "4",
doi = "10.2147/OTT.S93875",
language = "English (US)",
volume = "9",
pages = "2655--2665",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Emerging treatment options for myelofibrosis

T2 - Focus on pacritinib

AU - Chow, Vivian

AU - Weissman, Ashley

AU - O’Connell, Casey Lee

AU - Mehrvar, Azim

AU - Akhtari, Mojtaba

PY - 2016/5/4

Y1 - 2016/5/4

N2 - Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dysregulation has led to many clinical investigations for new treatment approaches. This review provides practical knowledge on the disease state, an overview of treatment options, and specifically focuses on the efficacy and safety of pacritinib in the management of MF. Pacritinib is a novel selective inhibitor of JAK2 and FMS-related tyrosine kinase 3 (FLT3) currently in Phase III trials for the treatment of MF. Thus far, studies have demonstrated clinical efficacy in reducing splenomegaly and constitutional symptoms. Common adverse events were gastrointestinal in nature, while hematologic toxicity was limited. However, it was announced that all ongoing clinical trials on pacritinib have been placed on hold by the US Food and Drug Administration in February 2016, due to concerns for increased intracranial hemorrhage and cardiac events. With comprehensive risk-benefit analysis of clinical trial data, the utility of pacritinib in the management of MF may be more clearly defined.

AB - Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic transformation. While there are limited curative treatments, the recent discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dysregulation has led to many clinical investigations for new treatment approaches. This review provides practical knowledge on the disease state, an overview of treatment options, and specifically focuses on the efficacy and safety of pacritinib in the management of MF. Pacritinib is a novel selective inhibitor of JAK2 and FMS-related tyrosine kinase 3 (FLT3) currently in Phase III trials for the treatment of MF. Thus far, studies have demonstrated clinical efficacy in reducing splenomegaly and constitutional symptoms. Common adverse events were gastrointestinal in nature, while hematologic toxicity was limited. However, it was announced that all ongoing clinical trials on pacritinib have been placed on hold by the US Food and Drug Administration in February 2016, due to concerns for increased intracranial hemorrhage and cardiac events. With comprehensive risk-benefit analysis of clinical trial data, the utility of pacritinib in the management of MF may be more clearly defined.

KW - FLT3

KW - JAK2

KW - Myeloproliferative neoplasms

KW - SB1518

UR - http://www.scopus.com/inward/record.url?scp=84965178295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965178295&partnerID=8YFLogxK

U2 - 10.2147/OTT.S93875

DO - 10.2147/OTT.S93875

M3 - Review article

C2 - 27226728

AN - SCOPUS:84965178295

VL - 9

SP - 2655

EP - 2665

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -